Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRAEDO AF: Edoxaban Monotherapy vs Edoxaban + Clopidogrel in AF with Stable Coronary Artery Disease
jRCTs031180119Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of edoxaban in nonvalvular atrial fibrillation (NVAF) and coronary arteriosclerosis (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Major bleeding and Clinically relevant non-major bleeding. Started Nov 2018; status: completed.
02
Drugs
edoxaban
03
Conditions
nonvalvular atrial fibrillation (NVAF)coronary arteriosclerosis
Beyond the preview
Go deeper on jRCTs031180119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180119.